2Pacetti SA,Gelone SP.Caspofungin acetate for treatment of invasive fungal infections.Ann Pharmacother,2003,37:90.
3Turner MS,Drew RH,et al.Emerging echinocandins for treatment of invasive fungal infections.Expert Opin Emerg Drugs,2006,11:231.
4Candoni A,Mestroni R,et al.Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.Eur J Haematol,2005,75:227.
2Stevens DA,Kan VL,Judson MA,et al.Practice guidelines for diseases caused by Aspergillus.Infectious Diseases Society of America.Clin Infect Dis,2000,30:696-709.
3Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus.Clin Infect Dis,2002,34:7-14.
4Denning DW,Kibbler CC,Barnes RA,et al.British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections.Lancet Infect Dis,2003,3:230-240.
5Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis.Clin Infect Dis,2004,38:161-189.
6Slavin MA,Szer J,Grigg AP,et al.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Intern Med J,2004,34:192-200.
7Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clin Infect Dis,2000,30:710-718.
4Amrein C, Bellenfant F, Novara A, et al . Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome[J] . Intensive Care Med, 2008,34(2) : 292.
5Pappas PG, Rex JH, Sobel JD, et al. Guideline for trealment of candidiasis[J ] . Clin Infect Dis, 2004, 38 (2):1 612 189.
6Ahmad SR, Singer J. Leissa BG. Congestive heart failure associated with it raconazole[J] . Lancet, 2001, 357(9 270) : 1 766.
